Clinically Relevant Reduction in Risk of Recurrence of Superficial Bladder Cancer Using 5-Aminolevulinic Acid-Induced Fluorescence Diagnosis: 8-Year Results of Prospective Randomized Study

Althausen, 1976, Non-invasive papillary carcinoma of the bladder associated with carcinoma in situ, J Urol, 116, 575, 10.1016/S0022-5347(17)58916-8 Smith, 1983, Prognostic significance of biopsy results of normal looking mucosa in a case of superficial bladder cancer, Br J Urol, 55, 665, 10.1111/j.1464-410X.1983.tb03400.x Heney, 1983, Superficial bladder cancer: progression and recurrence, J Urol, 130, 1083, 10.1016/S0022-5347(17)51695-X Flamm, 1989, The significance of bladder quadrant biopsies in patients with primary superficial bladder carcinoma, Eur Urol, 16, 81, 10.1159/000471541 Kriegmair, 1996, Detection of early bladder cancer by 5 aminolevulinic acid induced porphyrin fluorescence, J Urol, 155, 105, 10.1016/S0022-5347(01)66559-5 Filbeck, 1999, Clinical results of the transurethral resection and evaluation of superficial bladder carcinomas by means of FD after intravesical instillation of 5-aminolevulinic acid, J. Endourol, 13, 117, 10.1089/end.1999.13.117 De Dominicis, 2001, Role of 5-aminolevulinic acid in the diagnosis and treatment of superficial bladder cancer: improvement in diagnostic sensitivity, Urology, 57, 1059, 10.1016/S0090-4295(01)00948-7 Zaak, 2001, Endoscopic detection of transitional cell carcinoma with 5-aminolevulinic acid: results of 1012 fluorescence endoscopies, Urology, 57, 690, 10.1016/S0090-4295(00)01053-0 Filbeck, 2002, Reduction of recurrence rate of superficial bladder carcinoma after transurethral resection with 5-aminolevulinic acid induced fluorescence diagnosis, J Urol, 168, 67, 10.1016/S0022-5347(05)64833-1 Sobin, 1997, 50 Murphy, 1994, Tumors of the kidney, bladder and related urinary structures, 205 Smith, 1999, Bladder Cancer Clinical Guidelines Panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1 and Tis), J Urol, 162, 1697, 10.1016/S0022-5347(05)68208-0 Köhrmann, 1994, Der Wert der transurethralen Nachresektion beim oberflächlichen Harnblasenkarzinom, Akt Urol, 25, 208, 10.1055/s-2008-1058226 Holmang, 1999, Recurrence and progression in low grade papillary urothelial tumors, J Urol, 162, 702, 10.1097/00005392-199909010-00019 Schwaibold, 2000, Second transurethral resection detects histopathological changes worsening the prognosis in 25% of patients with pT1 bladder cancer, J Urol, 163, 153 Zurkirchen, 2004, Second transurethral resection of superficial transitional cell carcinoma of the bladder: a must even for experienced urologists, Urol Int, 72, 99, 10.1159/000075961 Klaen, 1991, Residual tumor discovered in routine second transurethral resection in patients with stage T1 transitional cell carcinoma of the bladder, J Urol, 146, 316, 10.1016/S0022-5347(17)37779-0 Miller, 1998, Leitlinien zur Diagnostik und Therapie des Harnblasenkarzinoms, Urologe A, 37, 440 Kriegmair, 2002, Transurethral resection for bladder cancer using 5-aminolevulinic acid induced fluorescence endoscopy versus white light endoscopy, J Urol, 168, 475, 10.1016/S0022-5347(05)64661-7 Grossman, 2004, The use of Hexvix and fluorescence cystoscopy as an adjunct in the diagnosis of stage TA/T1 urothelial cancer in the urinary bladder, J Urol, 171, 263, 10.1016/S0022-5347(18)37525-6 Filbeck, 2003, Reducing the risk of superficial bladder cancer recurrence with 5-aminolevulinic acid-induced fluorescence diagnosis: results of a 5-year study, Urologe A, 42, 1366, 10.1007/s00120-003-0355-y Daniltchenko, 2005, Long-term benefit of 5-aminolevulinic acid fluorescence assisted transurethral resection of superficial bladder cancer: 5-year results of a prospective randomized study, J Urol, 174, 2129, 10.1097/01.ju.0000181814.73466.14 Gwynn, 2006, Bladder cancer, Curr Opin Oncol, 18, 277, 10.1097/01.cco.0000219258.75961.1a